| Drug General Information |
| Drug ID |
D09POQ
|
| Former ID |
DIB004377
|
| Drug Name |
OM-174
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 1 |
[1]
|
|---|
| Company |
OM Pharma
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C53H102N2O20P2
|
| CAS Number |
CAS 171092-39-0
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Toll-like receptor 4 |
Target Info |
Modulator |
[2]
|
|---|
| Toll-like receptor 2 |
Target Info |
Modulator |
[2]
|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
HIF-1 signaling pathway
|
|
Phagosome
|
|
PI3K-Akt signaling pathway
|
|
Toll-like receptor signaling pathway
|
|
Pathogenic Escherichia coli infection
|
|
Salmonella infection
|
|
Pertussis
|
|
Legionellosis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Malaria
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Hepatitis B
|
|
Measles
|
|
Influenza A
|
|
Proteoglycans in cancer
|
|
Inflammatory bowel disease (IBD)
|
|
Rheumatoid arthritishsa04145:Phagosome
|
|
Herpes simplex infection
|
|
Rheumatoid arthritis
|
|
NetPath Pathway
|
IL5 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
IL4 Signaling PathwayNetPath_16:IL4 Signaling Pathway
|
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Toll receptor signaling pathwayP00054:Toll receptor signaling pathway
|
|
Pathway Interaction Database
|
Endogenous TLR signalingtoll_endogenous_pathway:Endogenous TLR signaling
|
|
Reactome
|
Ligand-dependent caspase activation
|
|
Toll Like Receptor 4 (TLR4) Cascade
|
|
MyD88:Mal cascade initiated on plasma membrane
|
|
MyD88-independent TLR3/TLR4 cascade
|
|
TRIF-mediated programmed cell death
|
|
MyD88 deficiency (TLR2/4)
|
|
IRAK4 deficiency (TLR2/4)
|
|
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
|
|
IKK complex recruitment mediated by RIP1
|
|
TRAF6 mediated induction of TAK1 complexR-HSA-1461957:Beta defensins
|
|
Toll Like Receptor TLR6:TLR2 Cascade
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Toll-Like Receptors Cascades
|
|
MyD88:Mal cascade initiated on plasma membrane
|
|
MyD88-independent cascade
|
|
Primary Focal Segmental Glomerulosclerosis FSGS
|
|
Spinal Cord Injury
|
|
Corticotropin-releasing hormone
|
|
Pathogenic Escherichia coli infection
|
|
Regulation of toll-like receptor signaling pathwayWP75:Toll-like receptor signaling pathway
|
|
IL1 and megakaryotyces in obesity
|
|
Human Complement System
|
|
Defensins
|
|
Regulation of toll-like receptor signaling pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01800812) Effects of OM-174 in Adult Patients With Solid Tumors. U.S. National Institutes of Health. |
|---|
| REF 2 | Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172. |
|---|
